Common Contracts

31 similar Merger Agreement contracts by Silverback Therapeutics, Inc., Kintara Therapeutics, Inc., Kubient, Inc., others

AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: PULMATRIX, Inc.; PCL Merger Sub, Inc.; PCL Merger Sub II, LLC; and cULLGEN Inc. Dated as of November 13, 2024
Merger Agreement • November 13th, 2024 • Pulmatrix, Inc. • Pharmaceutical preparations • Delaware
AutoNDA by SimpleDocs
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: ARCA BIOPHARMA, INC.; ATLAS MERGER SUB CORP.; ATLAS MERGER SUB II, LLC; and ORUKA THERAPEUTICS, INC. Dated as of April 3, 2024
Merger Agreement • April 3rd, 2024 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances • Delaware

THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of April 3, 2024, by and among ARCA BIOPHARMA, INC., a Delaware corporation (“Parent”), ATLAS MERGER SUB CORP., a Delaware corporation and wholly owned subsidiary of Parent (“First Merger Sub”), ATLAS MERGER SUB II, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent (“Second Merger Sub” and, together with First Merger Sub, “Merger Subs”), and ORUKA THERAPEUTICS, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined Section 1.

AGREEMENT AND PLAN OF MERGER by and among KINTARA THERAPEUTICS, INC., KAYAK MERGECO, INC. and TUHURA BIOSCIENCES, INC. Dated as of April 2, 2024
Merger Agreement • April 3rd, 2024 • Kintara Therapeutics, Inc. • Pharmaceutical preparations • Delaware

THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of April 2, 2024, by and among Kintara Therapeutics, Inc., a Nevada corporation (which shall reincorporate as a Delaware corporation in connection with the consummation of the transactions contemplated hereby) (“Parent”), Kayak Mergeco, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and TuHURA Biosciences, Inc., a Delaware corporation (the “Company”).

AGREEMENT AND PLAN OF MERGER by and among KINTARA THERAPEUTICS, INC., KAYAK MERGECO, INC. and TUHURA BIOSCIENCES, INC. Dated as of April 2, 2024
Merger Agreement • April 3rd, 2024 • Kintara Therapeutics, Inc. • Pharmaceutical preparations • Delaware

THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of April 2, 2024, by and among Kintara Therapeutics, Inc., a Nevada corporation (which shall reincorporate as a Delaware corporation in connection with the consummation of the transactions contemplated hereby) (“Parent”), Kayak Mergeco, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and TuHURA Biosciences, Inc., a Delaware corporation (the “Company”).

AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: AgeX Therapeutics, Inc., a Delaware corporation; CANARIA TRANSACTION CORPORATION, an Alabama corporation; and Serina THERAPEUTICS, INC., an Alabama corporation Dated as of August 29, 2023
Merger Agreement • August 30th, 2023 • AgeX Therapeutics, Inc. • Pharmaceutical preparations • Delaware
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION by and among: IMMUNOME, INC., a Delaware corporation; IBIZA MERGER SUB, INC., a Delaware corporation; and MORPHIMMUNE INC., a Delaware corporation Dated as of June 29, 2023
Merger Agreement • June 29th, 2023 • Immunome Inc. • Pharmaceutical preparations • Delaware
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION
Merger Agreement • May 30th, 2023 • Kubient, Inc. • Services-computer integrated systems design • Delaware

THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of May 24, 2023, by and among Kubient, Inc., a Delaware corporation (“Parent”), ADM Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and Adomni, Inc., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

AGREEMENT AND PLAN OF MERGER AND REORGANIZATION
Merger Agreement • May 30th, 2023 • Kubient, Inc. • Services-computer integrated systems design • Delaware

THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of May 24, 2023, by and among Kubient, Inc., a Delaware corporation (“Parent”), ADM Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and Adomni, Inc., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: ANGION BIOMEDICA CORP., a Delaware corporation; ARKHAM MERGER SUB, INC., a Delaware corporation; and elicio therapeutics, inc., a Delaware corporation Dated as of January 17, 2023
Merger Agreement • January 17th, 2023 • Angion Biomedica Corp. • Pharmaceutical preparations • Delaware

THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of January 17, 2023, by and among ANGION BIOMEDICA CORP., a Delaware corporation (“Parent”), ARKHAM MERGER SUB, INC., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and ELICIO THERAPEUTICS, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: SILVERBACK THERAPEUTICS, INC., a Delaware corporation; SABRE MERGER SUB, INC., a Delaware corporation; and ARS PHARMACEUTICALS, INC., a Delaware corporation Dated as of July 21, 2022
Merger Agreement • November 21st, 2022 • Bell Robert G. • Pharmaceutical preparations • Delaware

THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of July 21, 2022, by and among SILVERBACK THERAPEUTICS, INC., a Delaware corporation (“Parent”), SABRE MERGER SUB, INC. a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and ARS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: SILVERBACK THERAPEUTICS, INC., a Delaware corporation; SABRE MERGER SUB, INC., a Delaware corporation; and ARS PHARMACEUTICALS, INC., a Delaware corporation Dated as of July 21, 2022
Merger Agreement • November 18th, 2022 • Tanimoto Sarina • Pharmaceutical preparations • Delaware

THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of July 21, 2022, by and among SILVERBACK THERAPEUTICS, INC., a Delaware corporation (“Parent”), SABRE MERGER SUB, INC. a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and ARS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: SILVERBACK THERAPEUTICS, INC., a Delaware corporation; SABRE MERGER SUB, INC., a Delaware corporation; and ARS PHARMACEUTICALS, INC., a Delaware corporation Dated as of July 21, 2022
Merger Agreement • November 8th, 2022 • Silverback Therapeutics, Inc. • Pharmaceutical preparations • Delaware

THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of July 21, 2022, by and among SILVERBACK THERAPEUTICS, INC., a Delaware corporation (“Parent”), SABRE MERGER SUB, INC. a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and ARS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

AGREEMENT AND PLAN OF MERGER AND REORGANIZATION
Merger Agreement • September 27th, 2022 • Sesen Bio, Inc. • Pharmaceutical preparations • Delaware

THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of September 20, 2022, by and among SESEN BIO, INC., a Delaware corporation (“Parent”), SEAHAWK MERGER SUB, INC., a Delaware corporation and wholly-owned subsidiary of Parent (“Merger Sub”), and CARISMA THERAPEUTICS INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

AGREEMENT AND PLAN OF MERGER AND REORGANIZATION
Merger Agreement • August 11th, 2022 • Silverback Therapeutics, Inc. • Pharmaceutical preparations • Delaware
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: SILVERBACK THERAPEUTICS, INC., a Delaware corporation; SABRE MERGER SUB, INC., a Delaware corporation; and ARS PHARMACEUTICALS, INC., a Delaware corporation Dated as of July 21, 2022
Merger Agreement • July 21st, 2022 • Silverback Therapeutics, Inc. • Pharmaceutical preparations • Delaware

THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of July 21, 2022, by and among SILVERBACK THERAPEUTICS, INC., a Delaware corporation (“Parent”), SABRE MERGER SUB, INC. a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and ARS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

AGREEMENT AND PLAN OF MERGER
Merger Agreement • December 15th, 2020 • Anchiano Therapeutics Ltd. • Pharmaceutical preparations

THIS AGREEMENT AND PLAN OF MERGER (together with its exhibits and schedules, this “Agreement”) is made and entered into as of December 14, 2020, by and among Anchiano Therapeutics Ltd., an Israeli limited company (“Parent”), CMB Acquisition Ltd., an Israeli limited company and wholly-owned subsidiary of Parent (“Merger Sub”), and Chemomab Ltd., an Israeli limited company (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: SUNESIS PHARMACEUTICALS, INC. a Delaware corporation; SOL MERGER SUB, INC., a Delaware corporation; and VIRACTA THERAPEUTICS, INC., a Delaware corporation Dated as of November 29, 2020
Merger Agreement • November 30th, 2020 • Sunesis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware

THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of November 29, 2020, by and among Sunesis Pharmaceuticals, Inc., a Delaware corporation (“Parent”), Sol Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and Viracta Therapeutics, Inc., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: NTN BUZZTIME, INC. a Delaware corporation; BIT MERGER SUB, INC. a Delaware corporation; and BROOKLYN IMMUNOTHERAPEUTICS LLC a Delaware limited liability company Dated as of August 12, 2020
Merger Agreement • August 14th, 2020 • NTN Buzztime Inc • Television broadcasting stations • Delaware

THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of August 12, 2020, by and among NTN BUZZTIME, INC., a Delaware corporation (“Parent”), BIT MERGER SUB, INC., a Delaware corporation and wholly-owned subsidiary of Parent (“Merger Sub”), and BROOKLYN IMMUNOTHERAPEUTICS LLC, a Delaware limited liability company (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: REXAHN PHARMACEUTICALS, INC., a Delaware corporation; RAZOR MERGER SUB, INC., a Delaware corporation; and OCUPHIRE PHARMA, INC. a Delaware corporation Dated as of June 17, 2020
Merger Agreement • August 14th, 2020 • Rexahn Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware

THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of June 17, 2020, by and among REXAHN PHARMACEUTICALS, INC., a Delaware corporation (“Parent”), RAZOR MERGER SUB, INC., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and OCUPHIRE PHARMA, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: REXAHN PHARMACEUTICALS, INC., a Delaware corporation; RAZOR MERGER SUB, INC., a Delaware corporation; and OCUPHIRE PHARMA, INC. a Delaware corporation Dated as of June 17, 2020
Merger Agreement • June 19th, 2020 • Rexahn Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware

THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of June 17, 2020, by and among REXAHN PHARMACEUTICALS, INC., a Delaware corporation (“Parent”), RAZOR MERGER SUB, INC., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and OCUPHIRE PHARMA, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: DELMAR PHARMACEUTICALS, INC., a Nevada corporation; ADGERO ACQUISITION CORP., a Delaware corporation; and ADGERO BIOPHARMACEUTICALS HOLDINGS, INC. a Delaware corporation Dated as of June 9, 2020
Merger Agreement • June 10th, 2020 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware

THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of June 9, 2020, by and among DELMAR PHARMACEUTICALS, INC., a Nevada corporation (“Parent”), ADGERO ACQUISITION CORP., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and ADGERO BIOPHARMACEUTICALS HOLDINGS, INC., a Delaware corporation (the “Company”). Parent, Merger Sub and Company may each be referred to herein individually as a “Party” and collectively as the “Parties.” Certain capitalized terms used in this Agreement are defined in Exhibit A.

EX-2.1 2 d586213dex21.htm EX-2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: VERSARTIS, INC., a Delaware corporation; VELO MERGER SUB, INC. a Delaware corporation; and ARAVIVE BIOLOGICS, INC., a Delaware corporation Dated...
Merger Agreement • May 5th, 2020 • Delaware
AutoNDA by SimpleDocs
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: BIOPHARMX CORPORATION, a Delaware corporation; BITI MERGER SUB, INC. a Delaware corporation; and TIMBER PHARMACEUTICALS LLC, a Delaware limited liability company Dated as of January 28, 2020
Merger Agreement • January 29th, 2020 • BioPharmX Corp • Pharmaceutical preparations • Delaware

THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of January 28, 2020, by and among BIOPHARMX CORPORATION, a Delaware corporation (“Parent”), BITI MERGER SUB, INC., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and TIMBER PHARMACEUTICALS LLC, a Delaware limited liability company (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: NEWLINK GENETICS CORPORATION, a Delaware corporation; CYCLONE MERGER SUB, INC., a Delaware corporation; and LUMOS PHARMA, INC., a Delaware corporation
Merger Agreement • September 30th, 2019 • Newlink Genetics Corp • Pharmaceutical preparations • Delaware

THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of September 30, 2019, by and among NewLink Genetics Corporation, a Delaware corporation (“Parent”), Cyclone Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and Lumos Pharma, Inc., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: PROTEON THERAPEUTICS, INC., a Delaware corporation; REM 1 ACQUISITION, INC., a Delaware corporation; and ARTARA THERAPEUTICS, INC. a Delaware corporation Dated as of September 23, 2019
Merger Agreement • September 24th, 2019 • Proteon Therapeutics Inc • Biological products, (no disgnostic substances) • Delaware

THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this "Agreement") is made and entered into as of September 23, 2019, by and among PROTEON THERAPEUTICS, INC., a Delaware corporation ("Parent"), REM 1 Acquisition, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Proteon Merger Sub"), and ARTARA THERAPEUTICS, INC., a Delaware corporation (the "Company"). Certain capitalized terms used in this Agreement are defined in Exhibit A.

AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: GEMPHIRE THERAPEUTICS INC., a Delaware corporation; GR MERGER SUB INC., a Delaware corporation; and NEUROBO PHARMACEUTICALS, INC., a Delaware corporation Dated as of July 24, 2019
Merger Agreement • July 25th, 2019 • Gemphire Therapeutics Inc. • Pharmaceutical preparations • Delaware

THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of July 24, 2019, by and among GEMPHIRE THERAPEUTICS INC., a Delaware corporation (“Parent”), GR MERGER SUB INC., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and NEUROBO PHARMACEUTICALS, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: HISTOGENICS CORPORATION, a Delaware corporation; RESTORE MERGER SUB, INC., a Delaware corporation; and OCUGEN, INC., a Delaware corporation Dated as of April 5, 2019
Merger Agreement • April 8th, 2019 • Histogenics Corp • Orthopedic, prosthetic & surgical appliances & supplies • Delaware

THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of April 5, 2019, by and among Histogenics Corporation, a Delaware corporation (“Parent”), Restore Merger Sub, Inc. a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and Ocugen, Inc., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among:
Merger Agreement • March 7th, 2019 • GTX Inc /De/ • Pharmaceutical preparations • Delaware

THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of March 6, 2019, by and among GTx, Inc., a Delaware corporation (“Parent”) Grizzly Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and Oncternal Therapeutics, Inc., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

AGREEMENT AND PLAN OF MERGER AND REORGANIZATION
Merger Agreement • November 26th, 2018 • Edge Therapeutics, Inc. • Pharmaceutical preparations • Delaware

THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of November 23, 2018, by and among Edge Therapeutics, Inc., a Delaware corporation (“Parent”), ECHOS MERGER SUB, INC., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and PDS Biotechnology Corporation, a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: VERSARTIS, INC., a Delaware corporation; VELO MERGER SUB, INC. a Delaware corporation; and ARAVIVE BIOLOGICS, INC., a Delaware corporation Dated as of June 3, 2018
Merger Agreement • June 4th, 2018 • Versartis, Inc. • Pharmaceutical preparations • Delaware

THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of June 3, 2018, by and among VERSARTIS, INC., a Delaware corporation (“Parent”), VELO MERGER SUB, INC., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and ARAVIVE BIOLOGICS, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among:
Merger Agreement • October 30th, 2017 • Aviragen Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!